Lung CancerPhase 3NCT00008385
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
A Phase 3 study testing selenium in people with Lung Cancer, run by ECOG-ACRIN Cancer Research Group at 532 sites in 2 countries.
Trial summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- selenium
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,772 participants
- Where
- 532 sitesin 2 countries
- Study dates
- 18 Dec 2000to Nov 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0) non-small lung cancer (except carcinoid)*
- Completion of treatment for stage I lung cancer within the past 6 to 36 months and currently disease free
- At least one mediastinal lymph node sampled at resection NOTE: *Southwest Oncology Group (SWOG) and Cancer and Leukemia Group B (CALGB) patients must be T1, N0; CALGB patients may be T2, N0 provided disease was completely resected prior to June 1, 2001 and participation in CALGB 9633 was refused if offered
- 18 years old and over
- Eastern Cooperative Oncology Group performance status 0-1
- Bilirubin no greater than upper limit of normal (ULN)
Show all 9Show fewer
- Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) no greater than ULN
- Prior mineral, herbal, phytochemical, or vitamin supplementation allowed
- Concurrent non-selenium containing mineral, herbal, phytochemical, or vitamin supplementation allowed if schedule and supplementation prior to study remains unchanged
Who cannot join
- Evidence of new or recurrent lung cancer on chest x-ray within the past 8 weeks
- Synchronous lung or non-lung lesions or metastasis, even if resectable
- History of more than one primary lung cancer at any time
- Concurrent or other prior cancer within the past 5 years except localized non-melanoma skin cancer
- Prior or concurrent chemotherapy for recurrent lung cancer
- Prior or concurrent radiotherapy for recurrent lung cancer
Show all 11Show fewer
- Concurrent surgery
- Concurrent supplement(s) containing more than 50 micrograms of selenium
- STUDY PHASE:
- Free of disease
- Consumed at least 75% of tablets during 4-week run-in period
Trial locations and contacts
532 sites in 2 countries.
317 sites in 2 countries
United States300 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Tulane Cancer Center Office of Clinical Research
Alexandria, Louisiana, 71315-3198
Study site
Alexandria, Minnesota, 56308
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
McFarland Clinic, PC
Ames, Iowa, 50010
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Hospital District Sixth of Harper County
Anthony, Kansas, 67003
Fox Valley Hematology and Oncology - East Grant Street
Appleton, Wisconsin, 54911-3496
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Piedmont Hospital
Atlanta, Georgia, 30309
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Auburn Regional Center for Cancer Care
Auburn, Washington, 98002
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
WellStar Cobb Hospital
Austell, Georgia, 30106
Greater Baltimore Medical Center Cancer Center
Baltimore, Maryland, 21204
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410
Ochsner Health Center - Bluebonnet
Baton Rouge, Louisiana, 70809
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
St. Joseph Cancer Center
Bellingham, Washington, 98225
MeritCare Bemidji
Bemidji, Minnesota, 56601
Highlands Oncology Group - Springdale
Bentonville, Arkansas, 72712
Hematology Oncology Associates of Illinois - Berwyn
Berwyn, Illinois, 60402
St. Luke's Cancer Network at St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Study site
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
St. Joseph Medical Center
Bloomington, Illinois, 61701
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Boston University Cancer Research Center
Boston, Massachusetts, 02118
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Caritas St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135-2997
Veterans Affairs Medical Center - Brooklyn
Brooklyn, New York, 11209
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Illinois CancerCare - Canton
Canton, Illinois, 61520
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Illinois CancerCare - Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Eden Medical Center
Castro Valley, California, 94546
Iowa Blood and Cancer Care
Cedar Rapids, Iowa, 52402
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611-3013
Hematology and Oncology Associates
Chicago, Illinois, 60611
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, 60612-3785
University of Illinois Cancer Center
Chicago, Illinois, 60612-7243
Veterans Affairs Medical Center - Chicago Westside Hospital
Chicago, Illinois, 60612
Saint Joseph Hospital
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic - Chippewa Center
Chippewa Falls, Wisconsin, 54729
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
North Coast Cancer Care - Clyde
Clyde, Ohio, 43410
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, 43210-1240
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390
Praxair Cancer Center at Danbury Hospital
Danbury, Connecticut, 06810
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Danville Regional Medical Center
Danville, Virginia, 24541
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45429
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80224-2522
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Center for Cancer Treatment & Prevention at Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
John Smith, Jr. - Dalton McMichael Cancer Center at Morehead Memorial Hospital
Eden, North Carolina, 27288
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Sherman Hospital
Elgin, Illinois, 60120
Alexian Brothers Radiation Oncology
Elk Grove Village, Illinois, 60007
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital Cancer Program at Union Hospital
Elkton, Maryland, 21921
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Hematology Oncology Center
Elyria, Ohio, 44035
Swedish Medical Center
Englewood, Colorado, 80110
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
Evanston Hospital
Evanston, Illinois, 60201-1781
Center for Cancer Care at Exeter Hospital
Exeter, New Hampshire, 03833
North Bay Cancer Center
Fairfield, California, 94533
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Illinois CancerCare - Galesburg
Galesburg, Illinois, 61401
Adirondack Cancer Care - Glens Falls
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1198
Leo W. Jenkins Cancer Center at ECU Medical School
Greenville, North Carolina, 27834
Wayne Hospital
Greenville, Ohio, 45331
CCOP - Greenville
Greenville, South Carolina, 29615
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
Virginia Oncology Associates - Hampton
Hampton, Virginia, 23666
Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut, 06102-5037
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois, 60426
Hattiesburg Clinic, PA at Forrest General
Hattiesburg, Mississippi, 39401
Illinois CancerCare - Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Northern Montana Hospital
Havre, Montana, 59501
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
St. Peter's Hospital
Helena, Montana, 59601
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
Hawaii Medical Center - East
Honolulu, Hawaii, 96817
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Tripler Army Medical Center
Honolulu, Hawaii, 96859
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202-5289
Veterans Affairs Medical Center - Indianapolis
Indianapolis, Indiana, 46202
William N. Wishard Memorial Hospital
Indianapolis, Indiana, 46202
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Foote Memorial Hospital
Jackson, Michigan, 49201
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Midwest Center for Hematology/Oncology
Joliet, Illinois, 60432
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Truman Medical Center - Hospital Hill
Kansas City, Missouri, 64108
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
St. Joseph Medical Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
CCOP - Kansas City
Kansas City, Missouri, 64131
Research Medical Center
Kansas City, Missouri, 64132
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Columbia Basin Hematology
Kennewick, Washington, 99336
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
Kingsport, Tennessee, 37662
U.T. Medical Center Cancer Institute
Knoxville, Tennessee, 37920-6999
Howard Community Hospital
Kokomo, Indiana, 46904
Franciscan Skemp Healthcare - La Crosse Campus
La Crosse, Wisconsin, 54601
Gundersen Lutheran Center for Cancer and Blood
La Crosse, Wisconsin, 54601
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, 92093-0658
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Southwest Medical Center
Liberal, Kansas, 67901
Liberty Hospital
Liberty, Missouri, 64068
North Shore Oncology and Hematology Associates, Limited - Libertyville
Libertyville, Illinois, 60048
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80501
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Los Angeles, California, 90048
McKee Medical Center
Loveland, Colorado, 80539
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410-1894
Illinois CancerCare - Macomb
Macomb, Illinois, 61455
McDonough District Hospital
Macomb, Illinois, 61455
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Merle M. Mahr Cancer Center at Regional Medical Center of Hopkins County
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center at Elliot Hospital
Manchester, New Hampshire, 03103
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA - Maplewood
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California, 95901
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
St. Luke's Hospital
Maumee, Ohio, 43537
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Riddle Memorial Hospital Cancer Center
Media, Pennsylvania, 19063
University of Tennessee Cancer Institute - Memphis
Memphis, Tennessee, 38104
Veterans Affairs Medical Center - Memphis
Memphis, Tennessee, 38104
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Trinity CancerCare Center
Minot, North Dakota, 58701
Community Medical Center
Missoula, Montana, 59801
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
MBCCOP - Gulf Coast
Mobile, Alabama, 36604
Providence Cancer Center at Providence Hospital
Mobile, Alabama, 36608
Memorial Medical Center
Modesto, California, 95355
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
Moline, Illinois, 61265
Study site
Moline, Illinois, 61265
Illinois CancerCare - Monmouth
Monmouth, Illinois, 61462
OSF Holy Family Medical Center
Monmouth, Illinois, 61462
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey, 07962
El Camino Hospital Cancer Center
Mountain View, California, 94040
Mercy General Health Partners
Muskegon, Michigan, 49443
La Grange Oncology Associates - Geneva
Naperville, Illinois, 60563
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232-6838
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08903
Hospital of Saint Raphael
New Haven, Connecticut, 06511
CCOP - Ochsner
New Orleans, Louisiana, 70121
Canada17 sites
Tom Baker Cancer Centre - Calgary
Calgary, Alberta, T2N 4N2
Northeastern Ontario Regional Cancer Centre
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
St. Joseph's Hospital - Charlton Campus
Hamilton, Ontario, L8N 4A6
Margaret and Charles Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, K7L 5P9
London Regional Cancer Program at London Health Sciences Centre
London, Ontario, N6A 4L6
Hopital Notre-Dame du CHUM
Montreal, Quebec, H2L 4M1
Ottawa Hospital Regional Cancer Centre - General Campus
Ottawa, Ontario, K1H 8L6
L'Hopital Laval
Québec, G1V 4G5
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Algoma District Cancer Program at Sault Area Hospital
Sault Ste. Marie, Ontario, P6A 2C4
Cancer Care Program at Thunder Bay Regional Health Sciences
Thunder Bay, Ontario, P7B 6V4
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Trillium Health Centre - Mississauga Site
Toronto, Ontario, M9C 1A5
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
About this study
Official title: Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Read the detailed description
OBJECTIVES:
Primary Objective:
- Determine the efficacy of selenium in terms of reducing the incidence of second primary lung tumors in participants with previously resected stage I non-small cell lung cancer.
Secondary Objectives:
- Evaluate the qualitative and quantitative toxicity of selenium in these patients.
- Compare the incidence of specific cancers, mortality from cancer, and overall survival of participants treated with selenium vs those treated with placebo.
OUTLINE: This is a randomized, double-blinded, placebo-controlled, multicenter study. Participants are stratified according to smoking status (actively smoking or stopped less than 1 year ago vs. stopped at least 1 year ago vs. never smoked or no more than 100 cigarettes ever), gender, and stage and previous therapy (stage IA vs. stage IB with previous therapy vs. stage IB with no previous therapy). Participants are randomized in a 1:2 ratio to arm I and arm II.
- Arm I: Participants receive an oral yeast placebo as in arm II.
- Arm II: Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
Participants are followed annually (every 12 months) for 10 years.
PROJECTED ACCRUAL: A total of 1,960 participants will be accrued for this study within 4 years.
- Conditions
- Lung Cancer
- Being tested
- placebo, selenium
- Keywords
- stage I non-small cell lung cancer
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placeboOther
Given orally
seleniumDrug
Also called L-selenomethionine
Given orally
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Placebo comparator | Participants receive an oral yeast placebo as in arm II. Receives: Other: placebo |
| Arm II | Experimental | Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity. Receives: Drug: selenium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence Rate of Second Primary Lung Tumor
Incidence rate of second primary lung tumor was defined as the number of new second primary lung tumors per 100 population at risk in a year.
Measured: Assessed annually for 10 years after randomization
Secondary outcomes (2)
5-year Progression-free Survival Rate
Progression-Free Survival (PFS) was defined as the time from randomization to second primary lung cancer or recurrence. Cases without events have been censored at the time of last known alive. Kaplan-Meier method was used to estimate 5-year PFS rate.
Accurate determination of whether a cancer occurrence is recurrence or whether it is a second primary is critical. All suspicious lesions identified clinically and/or radiographically were verified histologically. Patients with at least one of the following is considered as having second primary lung cancer.
- Different histologic type
- Location in different lobe
- Location in contralateral lung
- Occurrence > 5 years after initial diagnosis
Measured: Assessed annually for 5 years after randomization
5-year Overall Survival Rate
Overall survival (OS) was defined as the time from randomization to death due to any cause. Cases without death had been censored at the time of last known alive. Kaplan-Meier method was used to estimate 5-year OS rate.
Measured: Assessed annually for 5 years after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study start18 Dec 2000
- Primary completionJun 2011
- Study completionNov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by ECOG-ACRIN Cancer Research GroupThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 1,772 participants (actual)
Sponsor and investigators
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), SWOG Cancer Research Network, North Central Cancer Treatment Group, NCIC Clinical Trials Group, Cancer and Leukemia Group B
- Responsible party
- Sponsor
- Investigators
- Daniel D. Karp, MD, Study chair, M.D. Anderson Cancer CenterOmer Kucuk, MD, Study chair, Barbara Ann Karmanos Cancer InstituteRandolph S. Marks, MD, Study chair, Mayo ClinicMichael R. Johnston, MD, FRCSC, Study chair, Nova Scotia Cancer CentreGerald H. Clamon, MD, Study chair, Holden Comprehensive Cancer CenterGord Okawara, MD, Study chair, Margaret and Charles Juravinski Cancer Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00008385
- Sponsor's protocol ID
- E5597
- Other IDs
- E5597, U10CA023318, CDR0000068402
- Status last verified
- Jun 2023
- First submitted
- 6 Jan 2001
- Last updated
- 5 Jul 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Study at a glance
From the registry record, last updated by the sponsor on 5 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT00008385
- Acronym / sponsor ID
- E5597
- Conditions
- Lung Cancer
- Keywords
- stage I non-small cell lung cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,772 participants (actual)
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Collaborators
- National Cancer Institute (NCI), SWOG Cancer Research Network, North Central Cancer Treatment Group, NCIC Clinical Trials Group, Cancer and Leukemia Group B
- Study start
- 18 Dec 2000 (actual)
- Primary completion
- Jun 2011 (actual)
- Study completion
- Nov 2019 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Posted 4 May 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Detailed description
OBJECTIVES:
Primary Objective:
- Determine the efficacy of selenium in terms of reducing the incidence of second primary lung tumors in participants with previously resected stage I non-small cell lung cancer.
Secondary Objectives:
- Evaluate the qualitative and quantitative toxicity of selenium in these patients.
- Compare the incidence of specific cancers, mortality from cancer, and overall survival of participants treated with selenium vs those treated with placebo.
OUTLINE: This is a randomized, double-blinded, placebo-controlled, multicenter study. Participants are stratified according to smoking status (actively smoking or stopped less than 1 year ago vs. stopped at least 1 year ago vs. never smoked or no more than 100 cigarettes ever), gender, and stage and previous therapy (stage IA vs. stage IB with previous therapy vs. stage IB with no previous therapy). Participants are randomized in a 1:2 ratio to arm I and arm II.
- Arm I: Participants receive an oral yeast placebo as in arm II.
- Arm II: Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
Participants are followed annually (every 12 months) for 10 years.
PROJECTED ACCRUAL: A total of 1,960 participants will be accrued for this study within 4 years.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I | Placebo comparator | Other: placeboParticipants receive an oral yeast placebo as in arm II. |
| Arm II | Experimental | Drug: seleniumParticipants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0) non-small lung cancer (except carcinoid)*
- 18 years old and over
- Eastern Cooperative Oncology Group performance status 0-1
- Bilirubin no greater than upper limit of normal (ULN)
- Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) no greater than ULN
Key exclusion criteria (11 listed)
- Evidence of new or recurrent lung cancer on chest x-ray within the past 8 weeks
- Synchronous lung or non-lung lesions or metastasis, even if resectable
- History of more than one primary lung cancer at any time
- Concurrent or other prior cancer within the past 5 years except localized non-melanoma skin cancer
- Prior or concurrent chemotherapy for recurrent lung cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placeboGiven orally | Other | Arm I |
| seleniumAlso: L-selenomethionineGiven orally | Drug | Arm II |
Primary outcome
Incidence Rate of Second Primary Lung Tumor
Time frame: Assessed annually for 10 years after randomization
Incidence rate of second primary lung tumor was defined as the number of new second primary lung tumors per 100 population at risk in a year.
2 secondary outcomes
5-year Progression-free Survival Rate
Time frame: Assessed annually for 5 years after randomization
5-year Overall Survival Rate
Time frame: Assessed annually for 5 years after randomization
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jul 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel D. Karp, MD study chair
M.D. Anderson Cancer Center
Omer Kucuk, MD study chair
Barbara Ann Karmanos Cancer Institute
Randolph S. Marks, MD study chair
Mayo Clinic
532 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing selenium in people with Lung Cancer, run by ECOG-ACRIN Cancer Research Group at 532 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 532 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 May 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence Rate of Second Primary Lung Tumor (time frame: Assessed annually for 10 years after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jul 2023.